FDA Approves ANDA216272 for Norepinephrine Bitartrate by Nephron
The FDA has approved ANDA216272, a generic formulation of Norepinephrine Bitartrate, submitted by Nephron.
Published: June 19, 2026
Updated: June 19, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiovascular / Vasopressor
Asset: Nephron
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Nephron
Indication
Signal assessment
Signal strength
high
Confidence level
high
Signalhigh
Confidencehigh
Why it matters
The FDA's approval of Nephron's generic Norepinephrine Bitartrate introduces a new competitor in the vasopressor market, which may disrupt pricing and market share dynamics. Portfolio teams must evaluate the implications for their existing products and adjust strategies accordingly.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timelines and pricing strategies from Nephron and competitors.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.